ZhuZhou QianJin Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
ZhuZhou QianJin Pharmaceutical Co Ltd cash flow-to-debt ratio. ZhuZhou QianJin Pharmaceutical Co Ltd (600479) has a Cash Flow-to-Debt Ratio of 0.17x as of September 2025, meaning its operating cash flow of CN¥288.83 Million could theoretically repay 0% of its total liabilities (CN¥1.66 Billion) in one year. Check earnings quality score of ZhuZhou QianJin Pharmaceutical Co Ltd to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of ZhuZhou QianJin Pharmaceutical Co Ltd (2002–2025)
Cash flow-to-debt ratio of ZhuZhou QianJin Pharmaceutical Co Ltd from 2002 to 2025. Historical debt coverage capacity for ZhuZhou QianJin Pharmaceutical Co Ltd across 24 annual periods. Check ZhuZhou QianJin Pharmaceutical Co Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
ZhuZhou QianJin Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (2002–2025)
ZhuZhou QianJin Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 2002 to 2025. Year-by-year debt coverage analysis for ZhuZhou QianJin Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see ZhuZhou QianJin Pharmaceutical Co Ltd (600479) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.30x | CN¥480.24 Million | CN¥1.61 Billion | ▲ +5.8% |
| 2024 | 0.28x | CN¥398.77 Million | CN¥1.42 Billion | ▲ +4.8% |
| 2023 | 0.27x | CN¥443.12 Million | CN¥1.65 Billion | ▼ -33.5% |
| 2022 | 0.40x | CN¥733.47 Million | CN¥1.82 Billion | ▲ +13.1% |
| 2021 | 0.36x | CN¥485.57 Million | CN¥1.36 Billion | ▼ -3.5% |
| 2020 | 0.37x | CN¥542.37 Million | CN¥1.47 Billion | ▲ +181.2% |
| 2019 | 0.13x | CN¥155.49 Million | CN¥1.18 Billion | ▼ -64.3% |
| 2018 | 0.37x | CN¥383.47 Million | CN¥1.04 Billion | ▲ +35.7% |
| 2017 | 0.27x | CN¥283.47 Million | CN¥1.05 Billion | ▲ +82.5% |
| 2016 | 0.15x | CN¥140.88 Million | CN¥948.21 Million | ▲ +71.5% |
| 2015 | 0.09x | CN¥67.48 Million | CN¥779.17 Million | ▼ -60.2% |
| 2014 | 0.22x | CN¥183.34 Million | CN¥843.20 Million | ▲ +8.0% |
| 2013 | 0.20x | CN¥137.63 Million | CN¥683.92 Million | ▼ -40.9% |
| 2012 | 0.34x | CN¥197.82 Million | CN¥581.18 Million | ▲ +334.3% |
| 2011 | 0.08x | CN¥22.58 Million | CN¥288.10 Million | ▼ -62.2% |
| 2010 | 0.21x | CN¥39.13 Million | CN¥188.65 Million | ▼ -11.3% |
| 2009 | 0.23x | CN¥73.54 Million | CN¥314.48 Million | ▲ +15.4% |
| 2008 | 0.20x | CN¥37.20 Million | CN¥183.66 Million | ▼ -51.6% |
| 2007 | 0.42x | CN¥79.26 Million | CN¥189.30 Million | ▼ -41.0% |
| 2006 | 0.71x | CN¥120.12 Million | CN¥169.13 Million | ▲ +88.8% |
| 2005 | 0.38x | CN¥76.50 Million | CN¥203.38 Million | ▲ +202.4% |
| 2004 | 0.12x | CN¥18.45 Million | CN¥148.38 Million | ▼ -54.1% |
| 2003 | 0.27x | CN¥50.96 Million | CN¥188.23 Million | ▲ +676.9% |
| 2002 | 0.03x | CN¥6.07 Million | CN¥174.31 Million | — |